These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31651452)

  • 41. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.
    Santini D; Santoni M; Conti A; Procopio G; Verzoni E; Galli L; di Lorenzo G; De Giorgi U; De Lisi D; Nicodemo M; Maruzzo M; Massari F; Buti S; Altobelli E; Biasco E; Ricotta R; Porta C; Vincenzi B; Papalia R; Marchetti P; Burattini L; Berardi R; Muto G; Montironi R; Cascinu S; Tonini G
    Oncotarget; 2016 May; 7(22):33381-90. PubMed ID: 27027342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
    Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.
    Shinohara N; Obara W; Tatsugami K; Naito S; Kamba T; Takahashi M; Murai S; Abe T; Oba K; Naito S
    Cancer Sci; 2015 May; 106(5):618-26. PubMed ID: 25711777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture.
    Thibault I; Al-Omair A; Masucci GL; Masson-Côté L; Lochray F; Korol R; Cheng L; Xu W; Yee A; Fehlings MG; Bjarnason GA; Sahgal A
    J Neurosurg Spine; 2014 Nov; 21(5):711-8. PubMed ID: 25170656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy.
    Hau HM; Thalmann F; Lübbert C; Morgul MH; Schmelzle M; Atanasov G; Benzing C; Lange U; Ascherl R; Ganzer R; Uhlmann D; Tautenhahn HM; Wiltberger G; Bartels M
    BMC Surg; 2016 Jul; 16(1):49. PubMed ID: 27444582
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
    Calvani N; Morelli F; Chiuri V; Gnoni A; Scavelli C; Fedele P; Orlando L; Maiello E; Lorusso V; Cinieri S
    Med Oncol; 2013; 30(2):578. PubMed ID: 23613183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 51. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
    Elaidi R; Harbaoui A; Beuselinck B; Eymard JC; Bamias A; De Guillebon E; Porta C; Vano Y; Linassier C; Debruyne PR; Gross-Goupil M; Ravaud A; Aitelhaj M; Marret G; Oudard S
    Ann Oncol; 2015 Feb; 26(2):378-85. PubMed ID: 25467013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
    Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
    Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
    Miyazaki A; Miyake H; Harada K; Fujisawa M
    Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between tyrosine-kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer.
    Gadd M; Pranavan G; Malik L
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1275. PubMed ID: 32767664
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
    Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.
    Wong MK; Jonasch E; Pal SK; Signorovitch JE; Lin PL; Wang X; Liu Z; Culver K; Scott JA; George DJ; Vogelzang NJ
    Expert Opin Pharmacother; 2015 Apr; 16(6):805-19. PubMed ID: 25766864
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
    Masini C; Iotti C; De Giorgi U; Bellia RS; Buti S; Salaroli F; Zampiva I; Mazzarotto R; Mucciarini C; Vitale MG; Bruni A; Lohr F; Procopio G; Caffo O; Nole F; Morelli F; Baier S; Buttigliero C; Ciammella P; Timon G; Fantinel E; Carlinfante G; Berselli A; Pinto C
    Eur Urol; 2022 Mar; 81(3):274-282. PubMed ID: 34602312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Zhou X; Fu G; Zu X; Xu Z; Li HT; D'souza A; Tulpule V; Quinn DI; Bhowmick NA; Weisenberger DJ; Liang G; Chen J
    Urol Oncol; 2022 Jan; 40(1):12.e13-12.e22. PubMed ID: 34454823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
    BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
    Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
    Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.